The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Dec. 15, 2022
Applicants:

Relay Therapeutics, Inc., Cambridge, MA (US);

D. E. Shaw Research, Llc, New York, NY (US);

Inventors:

Alexander M. Taylor, Cambridge, MA (US);

André Lescarbeau, Somerville, MA (US);

Elizabeth H. Kelley, Cambridge, MA (US);

Kelley C. Shortsleeves, Maynard, MA (US);

W. Patrick Walters, Westborough, MA (US);

Mark Andrew Murcko, Holliston, MA (US);

Thomas H. McLean, West Roxbury, MA (US);

Hakan Gunaydin, Somerville, MA (US);

Fabrizio Giordanetto, New York, NY (US);

Eric Therrien, Bronx, NY (US);

Assignees:

Relay Therapeutics, Inc., Cambridge, MA (US);

D.E Shaw Research, LLC., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 221/20 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01); C07D 491/107 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); C07D 221/20 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07D 491/107 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.


Find Patent Forward Citations

Loading…